New naloxone nasal spray at least doubles the dose
The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products.
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.
Related News Articles
Headline
The Food and Drug Administration sent a warning letter to Philips last month due to quality violations found at three of its medical device facilities earlier…
Blog
When a nonprofit hospital files the Internal Revenue Service (IRS) Form 990, Schedule H, it reports a wide range of activities and expenditures to demonstrate…
Perspective
All of America’s hospitals and health systems, regardless of ownership status, size or location, provide a vast range of benefits, programs and essential…
Headline
An AHA analysis released Sept. 10 highlights how tax-exempt hospitals provided nearly $150 billion in total benefits to their communities in 2022, the most…
Blog
The Paragon Health Institute has published a series of new reports once again alleging large-scale “fraud” in health care. This time their target is enrollment…
Headline
An article in the latest AHA Trustee Insights newsletter highlights the latest compliance enforcement trends in health care and offers steps for organizations…